title: [Treatment of allergic rhinitis with nasal mometasone furoate].
abstract: OBJECTIVE
  To evaluate the effects of nasal mometasone furoate on moderate to severe allergic rhinitis.
  
  
  METHODS
  Patients with moderate to severe allergic rhinitis were enrolled and received mometasone furoate nasal spray 200 microg once daily for four weeks. Four hundreds and sixty-three patients completed the study. We weekly interviewed the patients to evaluate the symptoms, and the affection of disease on night sleep and daily life. Mini Rhinoconjunctivitis Quality of Life Questionnaire (Mini-RQLQ) and Nocturnal Rhinoconjunctivitis Quality of Life Questionnaire (NRQLQ) were used to evaluate the quality of life.
  
  
  RESULTS
  The individual and total symptomatic scores of week 1, week 2 and week 4 decreased compared with baseline. The scores of Mini-RQLQ and NRQLQ of week 1, week 2 and week 4 decreased compared with baseline too. The scores of the next visit were significantly lower than those of the previous visit (P < 0.01).
  
  
  CONCLUSIONS
  A four-week administration of mometasone furoate nasal spray can effectively treat allergic rhinitis.
authors: Department of Otorhinolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing Institute of Otorhinolaryngology, Beijing, 100730 China.
authors: Luo
authors: L
authors: Zhang
authors: Geng
authors: G
authors: Xu
authors: Xiang-dong
authors: XD
authors: Wang
authors: Shi-xi
authors: SX
authors: Liu
authors: Yuan
authors: Y
authors: Li
authors: Shen-qing
authors: SQ
authors: Wang
authors: Bei-bei
authors: BB
authors: Yang
authors: Chun-quan
authors: CQ
authors: Zheng
authors: Cheng-shuo
authors: CS
authors: Wang
authors: Pin
authors: P
authors: Dong
authors: Zi-ping
authors: ZP
authors: Lin
authors: Hua
authors: H
authors: Zhang
authors: De-min
authors: DM
authors: Han
mesh_terms: D000281:Administration, Intranasal; D000293:Adolescent; D000328:Adult; D000368:Aged; D018926:Anti-Allergic Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D002648:Child; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D000068656:Mometasone Furoate; D011244:Pregnadienediols / Q000008:administration & dosage / Q000627:therapeutic use*; D011788:Quality of Life; D012221:Rhinitis, Allergic, Perennial / Q000188:drug therapy*; D011795:Surveys and Questionnaires; D055815:Young Adult
chemical_list: D018926:Anti-Allergic Agents; D011244:Pregnadienediols; D000068656:Mometasone Furoate